Mahana Therapeutics, developer of prescription digital therapeutics designed to empower patients with chronic conditions to live fuller lives, has signed an agreement with the Consumer Health division of Bayer, which will see its new digital therapeutics commercialised.

The partnership will bring together the expertise Mahana has in digital therapeutic development with Bayer’s intention to deliver products to help people take greater control of their own health through the use of digital solutions.

Earlier this year Bayer announced the launch of a new business unit. The Consumer Health division is focused on bringing new digitally-enabled precision health products to market. The division is prioritising the development of products that will enable people to use digital solutions to take control of their health, and facilitate their ability to make informed choices based on personal insights and novel delivery mechanisms.

David Evendon-Challis, head of R&D and chief scientific officer for the Consumer Health division of Bayer, said: “Digital therapeutics are a perfect addition to our portfolio of care and tap into new tech-savvy consumers looking for drug-free treatments as well as help eliminate gaps in care provision. We’re excited to partner with Mahana Therapeutics and enter the field of digital therapeutics in consumer health.”

The first product from Mahana Therapeutics was Mahana IBS which provides cognitive therapy to adults with the condition. The product was the first digital therapeutic to receive FDA clearance for the treatment of IBS.

Simon Levy, CEO of Mahana, said: “This historic partnership is among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics.

“Through this agreement, we can further expand the availability of our innovative prescription digital therapeutics for patients and their caregivers around the world who seek effective treatment for chronic conditions.”